Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer

Neal D Shore; Paul Sieber; Leanne Schimke; Adam Perzin; Scott Olsen

Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer

Urol Nurs. 2013 Sep-Oct;33(5):236-44, 248.

Authors

Neal D Shore¹, Paul Sieber², Leanne Schimke², Adam Perzin³, Scott Olsen⁴

Affiliations

¹ Atlantic Urology Clinics, USA.
² Lancaster Urology, Lancaster, PA, USA.
³ Delaware Valley Urology, Mt. Laurel, NJ, USA.
⁴ Watson Pharmaceuticals, Salt Lake City, UT, USA.

PMID: 24354113

Abstract

This multicenter, randomized, crossover, open-label study (ClinicalTrials.gov identifier: NCT01161563) assessed patients'and clinicians'perceptions of injection site tolerability and adverse events following the intramuscular injection of triptorelin pamoate or subcutaneous injection of leuprolide acetate in 107 male, patients with advanced prostate cancer.

Publication types

Comparative Study
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aged, 80 and over
Antineoplastic Agents, Hormonal / administration & dosage
Antineoplastic Agents, Hormonal / adverse effects
Cross-Over Studies
Gonadotropin-Releasing Hormone / agonists*
Humans
Leuprolide / administration & dosage*
Leuprolide / adverse effects
Male
Middle Aged
Prostatic Neoplasms / drug therapy*
Prostatic Neoplasms / nursing
Triptorelin Pamoate / administration & dosage*
Triptorelin Pamoate / adverse effects

Substances

Antineoplastic Agents, Hormonal
Triptorelin Pamoate
Gonadotropin-Releasing Hormone
Leuprolide

Associated data

ClinicalTrials.gov/NCT01161563